Table 1. Baseline demographic and clinical characteristics of children with MDR-TB receiving linezolid including data from 2 observational pharmacokinetic studies.
| Characteristic | MDRPK1 Multiple dose* (n = 9) | MDRPK2 Multiple dose (n = 8) | MDRPK2 Single dose (n = 31) | Combined (n = 48) |
|---|---|---|---|---|
| Median age in years (range) | 4.8 (0.6–13.8) | 4.9 (1.8–15.3) | 4.4 (1.1–14.6) | 4.6 (0.6–15.3) |
| Male gender (%) | 6 (66.7) | 6 (75.0) | 12 (38.7) | 24 (50.0) |
| Ethnicity (%) | ||||
| Black | 4 (44.4) | 6 (75.0) | 15 (48.4) | 25 (52.1) |
| Mixed race | 5 (55.6) | 2 (25.0) | 16 (51.6) | 23 (47.9) |
| HIV-infected (%) | 1 (11.1) | 1 (12.5) | 1 (3.2) | 3 (6.3) |
| WAZ < −2 (%) | 3 (33.3) | 3 (37.5) | 3 (9.7) | 9 (18.8) |
| Administration on day of PK sampling | ||||
| NGT (%) | 6 (66.7) | 0 (0.0) | 6 (19.4) | 12 (25.0) |
| Oral (%) | 3 (33.3) | 8 (100.0) | 25 (80.6) | 36 (75.0) |
| Formulation | ||||
| Whole tablet (%) | 1 (11.1) | 3 (37.5) | 1 (3.2) | 5 (10.4) |
| Crushed tablet (%) | 1 (11.1) | 1 (12.5) | 8 (25.8) | 10 (20.8) |
| Suspension (%) | 7 (77.8) | 4 (50.0) | 22 (71.0) | 33 (68.8) |
*None of the MDRPK1 patients had single dose.
The median age (range) of the children receiving each type of formulation are 13.0 years (7.2–15.3) for whole tablet (n = 5), 12.3 years (2.7–15.4) for crushed tablet (n = 12), and 2.6 years (0.6–9.6) for suspension (n = 37).
Abbreviations: MDR-TB, multidrug-resistant tuberculosis; NGT, nasogastric tube; PK, pharmacokinetic; WAZ, weight-for-age z-score.